Diassess Awarded Up to $21.9M from BARDA
Funding to expedite technology development, clinical trials, and FDA clearance The Biomedical Advanced Research and Development Authority (BARDA) has awarded a 5-year, (up to) $21.9 million contract to...
View ArticleBARDA Coronavirus Countermeasures Portfolio
To date, BARDA has built an impressive portfolio for novel coronavirus medical countermeasures. This portfolio consists of 33 companies developing a variety of measures ranging from diagnostics to...
View ArticleUpdated BARDA Funding Opportunities for Coronavirus
June 2020 Biomedical Advanced Research and Development Authority (BARDA) has two open funding opportunities focused on coronavirus, Broad Agency Announcement (BAA) and EZ-BAA. Submissions and meeting...
View ArticleExtension for Temporary AOI#14 (COVID-19) EZ BAA
AOI #4.1-D: Remote Patient Monitoring/Remote Diagnostic Tools BARDA is looking for diagnostic technologies with near-term impact to improve efficiency and effectiveness of the health infrastructure in...
View ArticleBARDA at NDFS
The BARDA DRIVe team presents an overview of the DRIVe program, DRIVe Catalysts, and holds a panel discussing the present DRIVe priorities and future vision. Source
View ArticleNDFS17 Video: Non-dilutive funding at BARDA for medical countermeasure R&D
Dr. Houchens is the Director of the Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures at Biomedical Advanced Research and Development Authority (BARDA), which...
View ArticleHow Non-Dilutive Funding Leads to Equity Investment: The Story of Enalare
Eagle Pharmaceuticals is making a $55-million equity investment in Enalare Therapeutics, reported Fierce Biotech in an article remarkably titled “Eagle swoops down to nab chunk of BARDA-backed Enalare...
View ArticleIs Non-Dilutive Funding the Key to Extending Runway in Biopharma and Biotech?
Since venture investment in life science companies began to slump in 2021, biopharma companies have tightened their belts notch by notch to squeeze more utility from each cent and extend their runways....
View ArticleBARDA Returns to NDFS
Join hundreds of life science industry leaders at The 18th Annual Non-Dilutive Funding Summit (NDFS) and find out more about non-dilutive funding for your R&D, including funding opportunities...
View ArticleBARDA at NDFS 2023, with Dr. Robert Johnson
The 18th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with directors at ARPA-H, BARDA, SEED, NIA, NHLBI, NIAID, NINDS, and CIRM, so the innovators could learn...
View Article
